Ovid Therapeutics (OVID) to Release Earnings on Tuesday

Key Points

• Q1 2026 earnings are scheduled before the market opens on May 12, with analysts forecasting ($0.12) EPS and $0.057M revenue; the earnings call is set for May 13 at 9:30 AM ET.
• Ovid recently beat estimates—reporting $0.06 EPS vs. a ($0.10) estimate and $0.72M revenue—but still shows weak profitability metrics (ROE −23.98%, net margin −240.11%).
• Shares trade around $2.92 with a market cap of about $384M, ~72% institutional ownership, and an average analyst consensus of "Moderate Buy" with a $4.63 price target.

Ovid Therapeutics (NASDAQ:OVID - Get Free Report) will likely be posting its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Ovid Therapeutics to post earnings of ($0.12) per share and revenue of $0.0570 million for the quarter. Individuals may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 9:30 AM ET.

Ovid Therapeutics (NASDAQ:OVID - Get Free Report) last issued its earnings results on Wednesday, March 18th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.16. The business had revenue of $0.72 million for the quarter, compared to analyst estimates of $0.06 million. Ovid Therapeutics had a negative return on equity of 23.98% and a negative net margin of 240.11%. On average, analysts expect Ovid Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Ovid Therapeutics Trading Down 0.5%

Shares of OVID traded down $0.02 during trading hours on Tuesday, hitting $2.92. The stock had a trading volume of 1,081,915 shares, compared to its average volume of 2,638,891. The company's fifty day simple moving average is $2.29 and its 200 day simple moving average is $1.81. The company has a debt-to-equity ratio of 0.09, a quick ratio of 8.97 and a current ratio of 8.97. Ovid Therapeutics has a 12-month low of $0.27 and a 12-month high of $3.11. The firm has a market cap of $384.42 million, a P/E ratio of -9.40 and a beta of 0.18.

Hedge Funds Weigh In On Ovid Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. LPL Financial LLC lifted its position in Ovid Therapeutics by 150.0% in the fourth quarter. LPL Financial LLC now owns 30,000 shares of the company's stock worth $49,000 after purchasing an additional 18,000 shares during the period. Bank of America Corp DE increased its holdings in shares of Ovid Therapeutics by 49.7% in the fourth quarter. Bank of America Corp DE now owns 56,733 shares of the company's stock valued at $53,000 after buying an additional 18,841 shares in the last quarter. Geode Capital Management LLC raised its stake in Ovid Therapeutics by 3.7% during the 4th quarter. Geode Capital Management LLC now owns 672,004 shares of the company's stock valued at $1,096,000 after purchasing an additional 23,984 shares during the period. Private Advisor Group LLC acquired a new stake in Ovid Therapeutics during the 3rd quarter valued at $33,000. Finally, Invesco Ltd. acquired a new stake in Ovid Therapeutics during the 4th quarter valued at $54,000. 72.24% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have commented on OVID. Weiss Ratings reissued a "sell (d-)" rating on shares of Ovid Therapeutics in a research report on Tuesday, April 21st. HC Wainwright raised their target price on Ovid Therapeutics from $2.00 to $4.00 and gave the company a "buy" rating in a research note on Thursday, April 9th. Wall Street Zen raised Ovid Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, March 21st. Wedbush reissued an "outperform" rating and issued a $7.00 price objective on shares of Ovid Therapeutics in a report on Wednesday, April 15th. Finally, BTIG Research restated a "buy" rating and issued a $4.00 target price on shares of Ovid Therapeutics in a research note on Thursday, March 26th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Ovid Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $4.63.

Ovid Therapeutics Company Profile

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company's lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.